Condition: Cancer · Alzheimer Disease · Sponsor: Valentina Garibotto
The main purpose is to evaluate initial clinical experiences and to explore whether the Vision.X system yields improved image quality and diagnostic performance compared to Vision 600.
This description comes directly from the study's public registry record.
Pr Valentina Garibotto Head of the Division of nuclear medicine and molecular imaging, MD · +41223727252 · valentina.garibotto@hug.ch
Always discuss trial participation with your own doctor first.
| Hopitaux Universitaires de Genève | Geneva, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07006155